Status:
UNKNOWN
Superficial Basal Cell Carcinoma Treatment With Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Methylaminolevulinate
Lead Sponsor:
Maastricht University Medical Center
Collaborating Sponsors:
Erasmus Medical Center
VieCuri Medical Centre
Conditions:
Superficial Basal Cell Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Skin cancer is the most common cancer in Caucasians, and a basal cell carcinoma (BCC) being the most common skin cancer with around 44,000 new tumours per year, and its incidence is still rising. In t...
Detailed Description
\- Basal cell carcinoma throughout the world Skin cancer is the most common form of cancer, with basal cell carcinoma (BCC) being the most common form of all skin cancers, and the incidence is still ...
Eligibility Criteria
Inclusion
- Minimal age of 18 years
- Histological proven BCC
- Primary BCC (no previous treatment)
- Being able to understand instructions
Exclusion
- Age under 18 years
- No histological proven BCC
- Recurrent BCC (previously treated)
- Not able to understand instructions
- Concomitant disease requiring systematic immunosuppressive treatment
- Genetic skin cancer disorders
Key Trial Info
Start Date :
August 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2015
Estimated Enrollment :
162 Patients enrolled
Trial Details
Trial ID
NCT01491711
Start Date
August 1 2013
End Date
April 1 2015
Last Update
January 31 2014
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Maastricht University Medical Center
Maastricht, Limburg, Netherlands, 6202 AZ
2
VieCuri Medical Centre
Venlo, Limburg, Netherlands, 5912 BL
3
Erasmus Medical Centre
Rotterdam, South Holland, Netherlands, 3015 CE